Last reviewed · How we verify

Cetuximab, Oxaliplatin, Leucovorin, 5FU, Irinotecan

Central European Cooperative Oncology Group · Phase 2 active Small molecule

Cetuximab, Oxaliplatin, Leucovorin, 5FU, Irinotecan is a Antineoplastic agents Small molecule drug developed by Central European Cooperative Oncology Group. It is currently in Phase 2 development for Colorectal cancer, Head and neck cancer.

Inhibits epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR) tyrosine kinases.

Inhibits epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR) tyrosine kinases. Used for Colorectal cancer, Head and neck cancer.

At a glance

Generic nameCetuximab, Oxaliplatin, Leucovorin, 5FU, Irinotecan
SponsorCentral European Cooperative Oncology Group
Drug classAntineoplastic agents
TargetEGFR, VEGFR
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 2

Mechanism of action

Cetuximab is a monoclonal antibody that binds to the epidermal growth factor receptor (EGFR) and inhibits its tyrosine kinase activity, thereby inhibiting tumor growth and angiogenesis. Oxaliplatin is a platinum-based chemotherapy drug that works by cross-linking DNA, thereby inhibiting DNA replication and transcription. Leucovorin is a folate analog that inhibits the metabolism of 5-fluorouracil (5-FU) and irinotecan, allowing them to exert their cytotoxic effects on cancer cells. 5-FU is a thymidylate synthase inhibitor that works by inhibiting the synthesis of thymidine, a nucleotide required for DNA replication. Irinotecan is a topoisomerase I inhibitor that works by inhibiting the enzyme topoisomerase I, which is involved in DNA replication and transcription.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Cetuximab, Oxaliplatin, Leucovorin, 5FU, Irinotecan

What is Cetuximab, Oxaliplatin, Leucovorin, 5FU, Irinotecan?

Cetuximab, Oxaliplatin, Leucovorin, 5FU, Irinotecan is a Antineoplastic agents drug developed by Central European Cooperative Oncology Group, indicated for Colorectal cancer, Head and neck cancer.

How does Cetuximab, Oxaliplatin, Leucovorin, 5FU, Irinotecan work?

Inhibits epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR) tyrosine kinases.

What is Cetuximab, Oxaliplatin, Leucovorin, 5FU, Irinotecan used for?

Cetuximab, Oxaliplatin, Leucovorin, 5FU, Irinotecan is indicated for Colorectal cancer, Head and neck cancer.

Who makes Cetuximab, Oxaliplatin, Leucovorin, 5FU, Irinotecan?

Cetuximab, Oxaliplatin, Leucovorin, 5FU, Irinotecan is developed by Central European Cooperative Oncology Group (see full Central European Cooperative Oncology Group pipeline at /company/central-european-cooperative-oncology-group).

What drug class is Cetuximab, Oxaliplatin, Leucovorin, 5FU, Irinotecan in?

Cetuximab, Oxaliplatin, Leucovorin, 5FU, Irinotecan belongs to the Antineoplastic agents class. See all Antineoplastic agents drugs at /class/antineoplastic-agents.

What development phase is Cetuximab, Oxaliplatin, Leucovorin, 5FU, Irinotecan in?

Cetuximab, Oxaliplatin, Leucovorin, 5FU, Irinotecan is in Phase 2.

What are the side effects of Cetuximab, Oxaliplatin, Leucovorin, 5FU, Irinotecan?

Common side effects of Cetuximab, Oxaliplatin, Leucovorin, 5FU, Irinotecan include Diarrhea, Fatigue, Nausea.

What does Cetuximab, Oxaliplatin, Leucovorin, 5FU, Irinotecan target?

Cetuximab, Oxaliplatin, Leucovorin, 5FU, Irinotecan targets EGFR, VEGFR and is a Antineoplastic agents.

Related